MicroRNA-155 acts as a diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma

Figures & data

Table 1. Relationship between miR-155 expression and clinicopathological characteristics.

Variable	N	miR-155 level		p Value
		High	Low
Age				.081
≧60	45	20	25
<60	51	31	20
Sex				.444
male	43	22	21
female	53	29	24
Tumour size (mm)				.001**
≧50	53	36	17
<50	43	15	28
Depth of tumour invasion				.002**
T1, T2	48	18	30
T3, T4	48	33	15
Lymph node metastasis				.576
Absent	47	25	22
Present	49	26	23
Distant metastasis				.322
Absent	46	26	20
Present	50	25	25
TNM Stage				.000**
I, II	48	16	32
III, IV	48	35	13

** p < .01

Figure 1. Relative miR-155 expression levels. The expression of miR-155 in ESCC tissues was significantly higher than that in matched adjacent samples (p < .001) and healthy control specimens (p < .001).

Table 2. Multivariate analysis of prognostic factors in ESCC.

Parameters	HR (95%CI)	p
Depth of tumour invasion	6.06 (1.62–22.67)	.007**
High miR-155 level	16.94 (3.33–86.12)	.001**
Low miR-155 level	–

** p < .01

Figure 2. The comparison of miR-155 expression in malignant tissues between ESCC patients with different ages (A), tumour sizes (B), tumour invasions (C) and TNM stages (D).

Figure 3. Receiver operating characteristics (ROC) curve analysis for the diagnostic value of miR-155 in ESCC. The AUC (the areas under the ROC curve) was 0.870 (95%CI = 0.797–0.943, p < .001), with a sensitivity of 83.5% and a specificity of 77.5%, respectively.

Figure 4. Kaplan-Meier analysis for the overall survival of patients with ESCC according to the expression of miR-155. Patients with high miR-155 expression had shorter overall survival than those with low expression. Log rank test proved that the difference was significant (p < .01).